Prospective Randomized Control Trial to Compare the Role of Injection Cerebrolysin for 10 Days Duration Against Placebo in Operated Cases of Degenerative Cervical Myelopathy

What Was Tested

Researchers studied Cerebrolysin in this randomized controlled trial publication.

Who Took Part

The study group was 30 patients.

Sixty patients received the injection Cerebrolysin for 10 days postoperatively.

The remaining 30 patients received a placebo.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Cerebrolysin and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the Cerebrolysin group a baseline to be compared against.

A time span of 10 days appears in the methods.

Ninety operated cases of mild to severe DCM were randomized into two groups.

Functional outcomes were measured using modified Japanese Orthopaedic Association (mJOA) scores and visual analogue scale (VAS).

The American Spinal Injury Association (ASIA) scale was used to document neurological recovery.

Hand function was assessed by measuring the grip strength and the upper limb function score the upper extremity motor mJOA plus upper extremity sensory mJOA score.

Assessments were performed and preoperatively and postoperatively and at one-month, three-month, six-month, and one-year following surgery.

What Was Measured

PubMed files the paper under topics including Cervical Vertebrae, Spinal Cord Diseases and Amino Acids.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Cerebrolysin in 30 patients over 10 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Spine), a journal based in United States.

More context: the Cerebrolysin compound page, all human trials.